Spdr S&p Biotech Etf ETF News

Smart Beta ETF report for IBB

Anastasia Amoroso, iCapital chief investment strategist, joins the 'Halftime Report' to discuss her take on the biotech sector for 2022.

It was another brutal year for cannabis stock investors in 2021 as the U.S. made very little regulatory progress on cannabis reform measures. Fortunately for cannabis stock investors, former hedge fun

Sector ETF report for FBT

Every week we highlight the most timely exchange-traded fund news, from new launches to inflows and performance.

Sector ETF report for IBB

Smart Beta ETF report for FBT

Sector ETF report for XBI

Sector ETF report for XBI

Which biotech ETF is the better choice?

Financial Sense Advisors Inc. lowered its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 2.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,562 shares of the exchange traded funds stock after selling 131 shares during the []

The "Halftime" crew discuss whether investors should position themselves in biotech in 2022.

Tygh Capital Management Inc. increased its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 1.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,703 shares of the exchange traded funds stock after purchasing an additional 1,235 shares during the period. Tygh Capital Management []

Sigma Planning Corp reduced its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 7.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,091 shares of the exchange traded funds stock after selling 704 shares during the period. Sigma Planning []

Nomura Warns Of "Potential Squeeze" Meltup Into New Year Amid Deteriorating Liquidity As cash indices were grinding to session lows yesterday, Nomura''s Charlie McElligott points out that there was substantial closing-out of downside (selling Puts / Put Spreads to close - notables incl ARKK and KWEB, as well as a bunch in single-name) along with some buying of upside (KRE Calls and Call Spreads, XBI CS, single-name ''stock replacement'' trades). In other words, constructive behavior, taking some protection off, others tilting to offense, and perhaps that explains the rebound overnight in futures To this ''constructive'' point, the Nomura strategist notes that the highs in spot VIX yesterday were made overnight and well-ahead of the ugly morning cash Equity session, where despite the ongoing selloff in stocks with ES -2.0% by late US noon-time, implied Vols just kept getting crunched and sharply lagged weak stocks (SPX 1m paper only +9bps, while QQQ and IWM vol finished down 30 and 18bps, respectively, while Skew was lower on all three major indices), as traders monetized hedges, or played the market constructively ...